Meeting report of the 6th Heidelberg Myeloma Workshop: current status and developments in diagnosis and therapy of multiple myeloma

Maximilian Merz; Marc S Raab; Hartmut Goldschmidt; Jens Hillengass

doi:10.1007/s00432-017-2463-x

Meeting report of the 6th Heidelberg Myeloma Workshop: current status and developments in diagnosis and therapy of multiple myeloma

J Cancer Res Clin Oncol. 2017 Dec;143(12):2521-2526. doi: 10.1007/s00432-017-2463-x. Epub 2017 Jun 26.

Authors

Maximilian Merz¹, Marc S Raab^{2

3}, Hartmut Goldschmidt^{2

4}, Jens Hillengass^{2

5}

Affiliations

¹ Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. maximilian.merz@med.uni-heidelberg.de.
² Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
³ Max Eder Group Experimental Therapies for Hematologic Malignancies, German Cancer Research Center, Heidelberg, Germany.
⁴ National Center for Tumor Diseases, Heidelberg, Germany.
⁵ Department of Radiology, German Cancer Research Center, Heidelberg, Germany.

PMID: 28653099
DOI: 10.1007/s00432-017-2463-x

Abstract

Purpose: The 6th Heidelberg Myeloma Workshop was held on May 5th and 6th, 2017 in the lecture hall of the University Hospital Heidelberg.

Methods and results: Main topics of the meeting were (1) biology and genomics of multiple myeloma, (2) diagnostics and prognostic factors, (3) role of immunotherapy in multiple myeloma, as well as (4) therapy of multiple myeloma-drugs and treatment strategies.

Conclusion: The landscape for the treatment of newly diagnosed and relapsed disease has significantly changed since the last Heidelberg Myeloma Workshop in 2015. Updates on the current developments were presented at the meeting.

Keywords: Autologous transplantation; Carfilzomib; Daratumumab; Elotuzumab; Ixazomib; Multiple myeloma.

Publication types

Congress

MeSH terms

Humans
Multiple Myeloma / diagnosis*
Multiple Myeloma / therapy*